Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신진호 | - |
dc.date.accessioned | 2017-05-29T05:29:02Z | - |
dc.date.available | 2017-05-29T05:29:02Z | - |
dc.date.issued | 2015-09 | - |
dc.identifier.citation | CURRENT MEDICAL RESEARCH AND OPINION, v. 31, NO 3, Page. 449-457 | en_US |
dc.identifier.issn | 0300-7995 | - |
dc.identifier.issn | 1473-4877 | - |
dc.identifier.uri | http://www.tandfonline.com/doi/abs/10.1185/03007995.2015.1006726 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/27508 | - |
dc.description.abstract | Objective: Clopidogrel is indicated for the treatment and prevention of peripheral vascular, cerebrovascular, and coronary artery diseases. This clinical trial was designed to demonstrate that clopidogrel napadisilate (CN) is not inferior to clopidogrel bisulfate (CB) with respect to its effectiveness in inhibiting platelet aggregation. Methods: This 4 week multi-center, prospective, open-label, randomized trial was conducted at five clinical centers in South Korea. Patients were randomized into the 75 mg CN group or the 75 mg CB group. Platelet aggregation was assessed by the VerifyNow assay. The primary outcome was the difference of the percentage P2Y(12) inhibition and the secondary outcome was the baseline and change in P2Y(12) reaction units (PRU). Results: There was no significant difference in the percentage P2Y(12) inhibition (CN vs. CB, 34.92 +/- 21.33% vs. 30.43 +/- 17.90%, p = 0.203). The mean difference of the percentage P2Y(12) inhibition between groups was 4.49%, their two-sided 95% confidence interval was -2.45% to 11.44%, and the lower bound (-2.45%) was greater than the acceptable non-inferiority margin of -9.0%. The baseline PRU was 96.67 +/- 76.76 in the CN group and 216.95 +/- 68.86 in the CB group (p = 0.121), and the change in the PRU was -3.32 +/- 51.71 in the CN group and 10.52 +/- 43.31 in the CB group (p = 0.106). Four subjects experienced AEs (6.3%, 5 events) in the CN group and 7 subjects (11.11%, 13 events) in the CB group without statistical significance (p = 0.364). With respect to serious adverse events, 2 events were reported in 2 subjects, 1 in each group. Conclusion: Clopidogrel napadisilate was not inferior to clopidogrel bisulfate in terms of antiplatelet efficacy and tolerability, and there were no clinically significant adverse events. | en_US |
dc.description.sponsorship | This research was financially sponsored by Hanmi Pharmaceutical Co. Ltd, Seoul, South Korea. The sponsor supported only laboratory testing, study medication, and clinical research coordinator expenses. The study was an investigator initiated trial, and the sponsor had no involvement in the study design, collection, analysis, and interpretation of data, or writing the manuscript. Hanmi Pharmaceutical also had no input into the decision to submit this article for publication. The authors had full access to all the data in the study, and the corresponding author had the final responsibility to submit the manuscript for publication. | en_US |
dc.language.iso | en | en_US |
dc.publisher | INFORMA HEALTHCARE | en_US |
dc.subject | Clopidogrel bisulfate | en_US |
dc.subject | Clopidogrel napadisilate | en_US |
dc.subject | Efficacy | en_US |
dc.subject | P2Y(12) | en_US |
dc.title | Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial | en_US |
dc.type | Article | en_US |
dc.relation.no | 3 | - |
dc.relation.volume | 31 | - |
dc.identifier.doi | 10.1185/03007995.2015.1006726 | - |
dc.relation.page | 449-457 | - |
dc.relation.journal | CURRENT MEDICAL RESEARCH AND OPINION | - |
dc.contributor.googleauthor | Kim, Sang Hoon | - |
dc.contributor.googleauthor | Sung, Jung-Hoon | - |
dc.contributor.googleauthor | Shin, JInho | - |
dc.contributor.googleauthor | Lee, Hyun Jong | - |
dc.contributor.googleauthor | Lee, Hyun Sang | - |
dc.contributor.googleauthor | Cho, Deok Kyu | - |
dc.contributor.googleauthor | Lim, Sang Wook | - |
dc.relation.code | 2015000730 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | jhs2003 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.